RxSight, Inc. Reports Second Quarter 2022 Financial Results by Seini Moimoi | Aug 8, 2022 | Portfolio News
Vaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs by Seini Moimoi | Aug 4, 2022 | Portfolio News
Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights by Seini Moimoi | Aug 4, 2022 | Portfolio News
Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies by Seini Moimoi | Aug 3, 2022 | Portfolio News
Nabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update by Seini Moimoi | Aug 3, 2022 | Portfolio News
Avenge Bio Announces FDA Clearance of the AVB-001 IND for the Treatment of Ovarian Cancer, a Novel Cellular Therapy Leveraging the LOCOcyteTM Immunotherapy Platform by Seini Moimoi | Aug 3, 2022 | Portfolio News
Axonics® Reports Second Quarter 2022 Financial Results by Seini Moimoi | Aug 1, 2022 | Portfolio News
Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVentures by Seini Moimoi | Jul 26, 2022 | Portfolio News
Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE) by Seini Moimoi | Jul 19, 2022 | Portfolio News
Nabriva Therapeutics Expands XENLETA® (lefamulin) Presence with Exclusive Agreement with Er-Kim Pharmaceuticals by Seini Moimoi | Jul 18, 2022 | Portfolio News
